Go to content
UR Home

Esters of bendamustine are by far more potent cytotoxic agents than the parent compound against human sarcoma and carcinoma cells

URN to cite this document:
DOI to cite this document:
Huber, Stefan ; Huettner, Johannes Philip ; Hacker, Kristina ; Bernhardt, Günther ; König, Jörg ; Buschauer, Armin
Date of publication of this fulltext: 09 Jul 2015 08:11


The alkylating agent bendamustine is approved for the treatment of hematopoietic malignancies such as non-Hodgkin lymphoma, chronic lymphocytic leukemia and multiple myeloma. As preliminary data on recently disclosed bendamustine esters suggested increased cytotoxicity, we investigated representative derivatives in more detail. Especially basic esters, which are positively charged under ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: daten@ur.de
0941 943 -5707

Contact persons